Fortune
1 week agoStartup companies
Obesity drugmaker BioAge targets $158 million in IPO
BioAge Labs Inc. is raising up to $157.5 million in its IPO targeting therapies for obesity and metabolic diseases.
The initial price range suggests a company market value of about $587 million.
Key investors include CEO Kristen Fortney and prominent venture capital firms. [ more ]